STOP-T1D

TrialNet ATG Prevention Study

Type 1 Diabetes TrialNet

About the STOP-T1D Study

TrialNet is testing whether a medicine, low-dose anti-thymocyte globulin (ATG), can delay or prevent type 1 diabetes (T1D) in people who are at a high risk for developing T1D within 2 years.

A previous TrialNet study in people newly diagnosed with T1D found that ATG may help people continue to make insulin and improve blood sugar levels, measured by a test called hemoglobin A1C (HbA1c).

Who Can Participate

This study is enrolling people ages 12-35 who are at the highest risk of developing T1D within 2 years.

Those at the highest risk have:

- 2 or more diabetes-related autoantibodies
- Abnormal blood sugar (using a glucose tolerance test)
- 1 additional high-risk marker

To be in the study, you will need to be up to date on vaccinations including COVID-19 and flu.

TrialNet Locations

This study will be available at TrialNet sites within the U.S. and internationally. For those willing to travel, assistance is available to help you get to the nearest location.

Know your risk of developing T1D

Lifetime



Next 2 years



TrialNet will test to see if you are eligible for this study after you have screened positive through the Pathway to Prevention Study.

Help us STOP-T1D
trialnet.org/stop-t1d

STOP-T1D

Type 1 Diabetes TrialNet

Treatment Schedule

Treatment

You will receive 2 doses of the study medicine (ATG or placebo) by intravenous infusion over 2 consecutive days. Each infusion will take at least 6 hours. The study staff will monitor your heart rate, blood pressure, and health closely during and after the medicine infusion. You will need to stay within 1 hour of the TrialNet site.

Post-Treatment

You will continue to have study visits for at least 24 months after your last dose of the study medicine. You can ask your TrialNet research team if these other visits can be completed at a location closer to you.

Ongoing Follow-Up

As part of the TrialNet family, we'll continue to follow you when this study is over. Your continued participation will be vital to helping us answer important questions about T1D prevention.

Before joining, the TrialNet research team will explain the study in detail, including your T1D risk scores, study risks and benefits, and answer all your questions.

Ask TrialNet

Have questions or need more information?

Contact:
(First Last Name)
(Phone Number)
(Email Address)

Study Design

Placebo-controlled (2-to-1):

Two out of three people will get the study medicine and the other one gets the placebo (inactive version of the study medicine).

Randomized:

A computer randomly selects who gets the study medicine and who gets the placebo. Neither you, nor your doctor, get to choose.

Help us STOP-T1D
trialnet.org/stop-t1d